Selecta Biosciences (SELB) Misses Q3 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
November 5, 2020 7:30 AM ESTPhase 3 DISSOLVE clinical program with Sobi ongoing to evaluate SEL-212; topline data expected in the second half of 2022IND filing for gene therapy expected in Q1 2021; preliminary Phase 1 data expected by end of 2021IgA nephropathy program underway with IND expected by end of 2021Ended quarter with cash position of $147.6 million with runway into the first quarter of 2023 Company to host conference call today at 8:30 a.m. ET
WATERTOWN, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) --... More
